RE: Question9 Aug 2023 14:20
Icecool and this is one of the key outcomes of AVA6000 P1A to date. Originally it was expected to be 4 cohorts of 3 patients each and take about a year. The fact they will have dosed over 30 already and had data from each is massive. This gives them so many options about P1b design with the aim of expediting the timelines to FDA approval and sales. Obvious additional benefits, no MTD found yet, MOA of Precision confirmed in Jan, Second prodrug initiated a long time ago now, no disease progression confirmed for some patients prior to the AGM. What's next? PFS and Efficacy info hopefully.